FDA Panel Backs Cholesterol Drug Trilipix

A Food and Drug Administration advisory panel concluded recently that Trilipix, the blockbuster cholesterol lowering drug from Abbott Labs, should continue to be marketed for use, despite a government study questioning the drug’s benefit. The panel further recommended that Trilipix be the focus of an additional study in order to see if the drug will reduce heart attacks when combined with other drugs such as Lipitor and Zocor.

While Trilipix is already on the market, the FDA’s panel was tasked with determining whether or not the drug needed additional testing and/or if the drug’s marketing approval for use with other statins (the most widely used class of cholesterol lowering drugs) should be revoked. Luckily for Abbott Labs, nine out of the 13 panelists voted that the drug’s label should keep the combination as an approved for use. The FDA is not legally required to follow the advice of its panels, but it usually does.

Bookmark and Share

Comments are closed.